Get the Stockscreener App
6.24
2.80%
0.17
Eupraxia Pharmaceuticals Inc stock is traded at $6.24, with a volume of 2,537.
It is up +2.80% in the last 24 hours and up +17.40% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$6.07
Open:
$6.1
24h Volume:
2,537
Relative Volume:
0.05
Market Cap:
$226.55M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-8.1039
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
+4.44%
1M Performance:
+17.40%
6M Performance:
+106.28%
1Y Performance:
+160.00%
1-Day Range:
$6.07
$6.30
1-Week Range:
$5.7476
$6.30
52-Week Range:
$2.20
$7.19
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.30 | 307.12M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX) Comprehensive Trading Strategy Report (EPRX:CA) - news.stocktradersdaily.com
Trend Tracker for (EPRX.WT.A) - news.stocktradersdaily.com
Multi factor analysis applied to Eupraxia Pharmaceuticals Inc.Quarterly Profit Report & Reliable Trade Execution Plans - newser.com
Analysts Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Price Target at $11.00 - Defense World
Long term hold vs stop loss in Eupraxia Pharmaceuticals Inc.Trade Risk Assessment & Free High Return Stock Watch Alerts - newser.com
Using fundamentals and technicals on Eupraxia Pharmaceuticals Inc.Quarterly Portfolio Review & Advanced Swing Trade Entry Plans - newser.com
(EPRX) Strategic Investment Guide (EPRX:CA) - news.stocktradersdaily.com
When is the best time to exit Eupraxia Pharmaceuticals Inc.Day Trade & Free Risk Controlled Daily Trade Plans - newser.com
Eupraxia Pharmaceuticals Reports Positive Results in EoE Trial and Plans Expansion - MSN
Can Eupraxia Pharmaceuticals Inc. stock double in next 5 years2025 Big Picture & Weekly High Return Opportunities - newser.com
Sentiment analysis tools applied to Eupraxia Pharmaceuticals Inc.July 2025 Price Swings & Weekly Breakout Stock Alerts - newser.com
Using flow based indicators on Eupraxia Pharmaceuticals Inc.July 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Is Eupraxia Pharmaceuticals Inc. (X43) stock considered safe havenEarnings Growth Summary & Consistent Return Strategy Ideas - newser.com
Can Eupraxia Pharmaceuticals Inc. (X43) stock attract analyst upgradesProfit Target & Trade Opportunity Analysis - newser.com
Detecting price anomalies in Eupraxia Pharmaceuticals Inc. with AIJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Eupraxia Pharmaceuticals (NASDAQ:EPRX) - MarketBeat
(EPRX) Trading Signals (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What is HC Wainwright’s Estimate for EPRX Q3 Earnings? - Defense World
Quantitative breakdown of Eupraxia Pharmaceuticals Inc. recent movePortfolio Risk Summary & Weekly Breakout Watchlists - newser.com
Will Eupraxia Pharmaceuticals Inc. stock outperform Nasdaq indexEarnings Beat & High Accuracy Swing Trade Signals - newser.com
What is HC Wainwright's Estimate for EPRX Q3 Earnings? - MarketBeat
(EPRX.WT.A) Trading Report (EPRX.WT.A:CA) - news.stocktradersdaily.com
Why Eupraxia Pharmaceuticals Inc. is moving today2025 Bull vs Bear & Verified Entry Point Detection - newser.com
Historical volatility pattern of Eupraxia Pharmaceuticals Inc. visualizedJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Measuring Eupraxia Pharmaceuticals Inc.’s beta against major indices2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Technical analysis overview for Eupraxia Pharmaceuticals Inc. stock2025 Analyst Calls & Safe Entry Point Identification - newser.com
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
This small Canadian pharma stock is undervalued, analyst says - Cantech Letter
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Shares Down 2.5%What's Next? - MarketBeat
Why Eupraxia Pharmaceuticals Inc. (X43) stock could outperform next year2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Will Eupraxia Pharmaceuticals Inc. (X43) stock beat Nasdaq index returnsLayoff News & Real-Time Volume Surge Alerts - newser.com
What’s next for Eupraxia Pharmaceuticals Inc. stock price2025 Fundamental Recap & Weekly High Momentum Picks - newser.com
Eupraxia Pharmaceuticals Secures $80.5 Million in Public Offering - MSN
Raymond James Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Trend Tracker for (EPRX) (EPRX:CA) - news.stocktradersdaily.com
Craig-Hallum Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering - MSN
Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study - Benzinga
Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals stock maintains Overweight rating at Cantor Fitzgerald - Investing.com India
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):